Dronabinol in obstructive sleep apnea: PACE trial (phase II RCT)

Introduction and clinical context

The study Dronabinol in obstructive sleep apnea: PACE trial (phase II RCT) (PubMed · 2018) is part of the scientific research on the use of cannabinoids in sleep apnea.

In obstructive sleep apnea (OSA), the synthetic cannabinoid dronabinol was evaluated in trials (including a phase II study), with signs of a reduction in the apnea-hypopnea index and in daytime sleepiness. Despite the interest, sleep guidelines do not recommend cannabinoids as a standard treatment for OSA, whose reference management includes CPAP. The research remains exploratory.

Understanding what science shows about the use of cannabinoids in sleep apnea helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Phase II RCT: dronabinol reduced the apnea-hypopnea index (AHI) and daytime sleepiness in OSA. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In obstructive sleep apnea, the hypothesis involves the modulation, by cannabinoids such as dronabinol, of upper-airway stability and respiratory control during sleep, via endocannabinoid signaling. Safety is a critical point: sedative effects can interfere with sleep architecture, and chronic use lacks long-term data. For this reason, guidelines do not recommend cannabinoids as a standard treatment, keeping CPAP as the reference. Any studies occur in a controlled context, with specialized sleep assessment.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2018). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis treat sleep apnea?

Dronabinol showed positive signs in trials, but it is not standard treatment; the reference management includes CPAP.

What is the apnea-hypopnea index?

It is the measure that quantifies the pauses and reductions in breathing per hour of sleep.